The Office of the Excellence Action Plan of China’s STM (Scientific, Technical and Medical) Journals has officially released the list of high-start new titles selected for 2025. Chemical Biology & Therapeutics, a life-science journal in English sponsored by the Chinese Medical Association and published by the Beijing Huairou Science City Institute for Innovation in Life-Science Industry (hereinafter “the Life-Science Industry Institute”), was successfully selected, marking a major step for Huairou Science City in building a world-class academic-exchange platform.
The journal Chemical Biology & Therapeutics focuses on the strategic priority of “serving the people’s life and health,” focuses on the interface of chemical biology and disease diagnosis & therapy, highlights translational applications, and aims to fill critical gaps in these niche areas.
As the publishing institute, the Life-Science Industry Institute was jointly founded by the Administrative Committee of Huairou Science City in collaboration with Peking University, the University of Chinese Academy of Sciences (UCAS), and the Institute of Automation of the Chinese Academy of Sciences. It is dedicated to accelerating technology transfer and boosting industrial innovation in the life sciences. Rooted in Huairou Science City, the Life-Science Industry Institute will leverage the city’s dense cluster of scientific facilities and collaborative innovation ecosystem to provide solid support for the journal and help build a distinctive, internationally influential, high-level academic platform.
Phase II of the Excellence Action Plan of China’s STM Journals (2024–2028) is implemented by seven authorities, including the China Association for Science and Technology. It aims to pre-emptively fill disciplinary gaps and aggregate high-quality scholarly resources. This year 70 projects were selected; English journals alone cover 53 strategic frontiers such as artificial intelligence, quantum science & technology, and biomedical engineering. The selection underscores the journal’s broad development prospects.
Professor WANG Wei, Fellow of the Royal College of Physicians (UK), will serve as Editor-in-Chief. Nobel laureate Carolyn Bertozzi is expected to join as Honorary Editor-in-Chief, and Professor LANG Minglin of UCAS will act as Journal Director and Deputy Editor-in-Chief. The editorial board is academically strong and globally minded. In addition, the journal will partner with the American Chemical Society (ACS) to align with international publishing standards and dissemination channels, ensuring best-in-class operations. The title has already passed the review for an international ISSN and will receive its official number shortly.
In the future, Chemical Biology & Therapeutics will continue to capitalize on Huairou Science City’s concentration of scientific capabilities, bridging basic research, clinical translation, and industrial application, thereby advancing the high-quality development of China’s scientific journals and enhancing the nation’s voice in international academia.
Seizing this opportunity, Huairou Science City will further integrate regional innovation resources, build a robust scholarly publishing and exchange ecosystem, and steadily boost its academic influence and innovation-generating capacity in relevant fields.